Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Two New U.S. Patents Issued to Dyadic International

April 7, 2011 By Bio-Medicine.Org

JUPITER, Fla., April 7, 2011 /PRNewswire/ — Dyadic
International, Inc. (“Dyadic”) (OTC Pink: DYAI), a global
biotechnology company focused on the discovery, development,
manufacture and sale of enzyme and protein products for the
bioenergy, industrial enzyme and biopharmaceutical industries,
announced today that it has been issued U.S. Patent No. 7,906,309
entitled, “Expression-Regulating Sequences and Expression
Products in the Field of Filamentous Fungi”
and U.S. Patent No.
7,892,812 entitled, “Chrysosporium Cellulase and Methods of
Use”
by the United States Patent and Trademark Office
(“USPTO”).

(Logo: http://photos.prnewswire.com/prnh/20091214/DYADICLOGO)

U.S. Patent No. 7,906,309

“Expression-Regulating Sequences and Expression Products in
the Field of Filamentous Fungi”

The inventions embodied by this patent are genes and their
corresponding enzymes from glycosyl hydrolase family 10 having
xylanase activity which are derived from Chysosporium fungal
strains. Other related applications claim cellobiohydrolases and
glyceraldehyde phosphate dehydrogenases. These enzymes have proven
to be effective in breaking down the major component of plant cell
walls, commonly known as lignocellulosic biomass, into fermentable
C5 sugars which can be used in the production of biofuels and
biochemicals.  These genes and enzymes were isolated from
Dyadic’s patented and proprietary C1 fungus and identified through
the genome annotation project conducted by Dyadic in conjunction
with Scripps Florida.

Dyadic’s President and Chief Executive Officer, Mark Emalfarb,
stated, “This patent protects Dyadic’s ability to use its C1
technology to make fermentable C5 sugars in addition to the C6
sugars allowed by our previously awarded biofuels patent.”

U.S. Patent No. 7,892,812

“Chrysosporium Cellulase and Methods

‘/>”/>

SOURCE

Related Articles Read More >

UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial
CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices

DeviceTalks Weekly.

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech